• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
    • Oncology
    • Neurology
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Patients with Breast Cancer
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
    • Oncology
    • Neurology
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Patients with Breast Cancer
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
17OctOctober 17, 2025

TACTIVE-N: Phase 2 Study of Neoadjuvant Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, or Anastrozole in Postmenopausal ER+/Human Epidermal Growth Factor Receptor 2-Negative Localized Breast Cancer

17OctOctober 17, 2025

Patient-Reported Outcomes (PROs) with Vepdegestrant (VEP) vs Fulvestrant (FUL) in Patients (pts) with Estrogen Receptor (ER) 1 Gene Mutated (ESR1m) ER+/Human Epidermal Growth Factor Receptor 2 (HER2): Advanced Breast Cancer (aBC) in the Phase 3 VERITAC-2 Trial

23SepSeptember 23, 2025

ISSX 2025

21SepSeptember 21, 2025

Absorption, Metabolism, Excretion, and Pharmacokinetics of [14C] Vepdegestrant in Healthy Adult Participants

16SepSeptember 16, 2025

ACCP 2025

14SepSeptember 14, 2025

A Relative Bioavailability Study of Vepdegestrant Tablets in Healthy Adult Participants

30MayMay 30, 2025

ASCO 2025

30MayMay 30, 2025

Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Results of the Global, Randomized, Phase 3 VERITAC-2 Study

28MayMay 28, 2025

ASCPT 2025

28MayMay 28, 2025

The Effect of Carbamazepine on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Healthy Adults

  Prev123…6Next  
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE